85% of trials fail to recruit enough patients. 40% drop out. The root cause? Patients don't understand what they're signing up for. Hoot delivers physician-led education that drives enrollment, retention, and diversity.
See How It WorksThe clinical trial industry faces mounting pressures from patient recruitment failures, retention challenges, and lack of diversity—all rooted in education gaps.
Patients don't know trials exist, fear being "guinea pigs," or don't understand the process. 37% cite lack of awareness as the primary barrier.
15-40% of enrolled participants drop out before completion due to lack of engagement, protocol confusion, and loss of motivation.
75% of trial participants are white. Historical mistrust, lack of culturally appropriate materials, and limited community outreach perpetuate disparities.
"Current clinical trial models are unsustainable. Patient recruitment and retention remain the most taxing aspects of trial management—and the #1 issue researchers face after receiving funding."
— Industry Analysis, Clinical Trials Comprehensive Report, January 2026
Hoot delivers physician-led video education via SMS and email—meeting patients where they are with content that builds understanding, addresses fears, and motivates action.
A 5-message sequence that transforms confusion and fear into informed enrollment
Physician-led video education delivered at every critical decision point—from recruitment through completion.
Address the awareness gap with educational content that explains clinical trials, safety protections, and patient rights—before the first contact.
Keep participants engaged with ongoing education, visit preparation, and motivation reinforcement throughout the trial lifecycle.
Culturally tailored content that addresses historical mistrust and reaches underserved communities through trusted channels.
Transform 20+ page consent forms into digestible, multimedia experiences that ensure true comprehension—not just signatures.
Sickle cell disease predominantly affects Black and African American patients—the same population most underrepresented in clinical trials. With breakthrough gene therapies like Casgevy and Lyfgenia now FDA-approved, patient education has never been more critical.
Based on industry data, even modest improvements in enrollment and retention yield significant cost savings.
Access our comprehensive clinical trial analyses with data from 60+ industry sources including Nature, The Lancet, FDA, NIH, and leading pharmaceutical databases.
A comprehensive analysis of how clinical trials operate in 2025-2026, covering escalating costs, recruitment failures, diversity gaps, protocol complexity, and declining success rates—synthesized from 60+ industry sources.
Identifies five high-value integration opportunities where Hoot delivers measurable impact—from patient recruitment education and retention to diversity outreach, site staff training, and informed consent enhancement.
In 30 minutes, we'll show you:
